-$0.98 EPS Expected for KemPharm Inc (KMPH) This Quarter

Analysts expect KemPharm Inc (NASDAQ:KMPH) to report ($0.98) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for KemPharm’s earnings. The highest EPS estimate is ($0.86) and the lowest is ($1.18). KemPharm posted earnings per share of ($0.44) during the same quarter last year, which indicates a negative year-over-year growth rate of 122.7%. The firm is expected to announce its next quarterly earnings results on Thursday, August 9th.

On average, analysts expect that KemPharm will report full year earnings of ($4.11) per share for the current financial year, with EPS estimates ranging from ($4.41) to ($3.68). For the next financial year, analysts expect that the business will post earnings of ($2.66) per share, with EPS estimates ranging from ($3.47) to ($2.10). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow KemPharm.

KemPharm (NASDAQ:KMPH) last released its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.41).

A number of analysts have recently weighed in on KMPH shares. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a research report on Friday, March 30th. Oppenheimer set a $13.00 target price on KemPharm and gave the company a “buy” rating in a research report on Monday, April 2nd. Roth Capital set a $10.00 target price on KemPharm and gave the company a “buy” rating in a research report on Monday, April 2nd. ValuEngine upgraded KemPharm from a “sell” rating to a “hold” rating in a research report on Friday, April 6th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $11.00 target price on shares of KemPharm in a research report on Thursday, May 10th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $11.21.

In other KemPharm news, EVP Daniel L. Cohen purchased 7,900 shares of the stock in a transaction dated Tuesday, May 15th. The stock was bought at an average price of $6.45 per share, with a total value of $50,955.00. Following the acquisition, the executive vice president now owns 35,500 shares of the company’s stock, valued at $228,975. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 25.90% of the stock is currently owned by insiders.

Several institutional investors have recently bought and sold shares of KMPH. ING Groep NV acquired a new position in shares of KemPharm during the 1st quarter worth $1,102,000. JPMorgan Chase & Co. raised its holdings in shares of KemPharm by 15,976.2% during the 1st quarter. JPMorgan Chase & Co. now owns 100,637 shares of the specialty pharmaceutical company’s stock worth $795,000 after buying an additional 100,011 shares in the last quarter. Change Path LLC acquired a new position in shares of KemPharm during the 1st quarter worth $479,000. Royal Bank of Canada raised its holdings in shares of KemPharm by 1,847.1% during the 1st quarter. Royal Bank of Canada now owns 24,125 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 22,886 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of KemPharm by 10.9% during the 1st quarter. Victory Capital Management Inc. now owns 179,737 shares of the specialty pharmaceutical company’s stock worth $1,420,000 after buying an additional 17,660 shares in the last quarter. 36.46% of the stock is owned by institutional investors.

Shares of NASDAQ:KMPH traded down $0.20 during trading on Monday, reaching $4.05. 90,629 shares of the company traded hands, compared to its average volume of 155,090. The company has a market cap of $62.69 million, a price-to-earnings ratio of -1.37 and a beta of -0.19. The company has a debt-to-equity ratio of -1.13, a quick ratio of 2.83 and a current ratio of 2.83. KemPharm has a 52 week low of $2.45 and a 52 week high of $8.40.

About KemPharm

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's lead product candidates include KP415 and KP484, which are extended release prodrugs of methylphenidate for the treatment of attention deficit hyperactivity disorder.

Featured Article: Dividend

Get a free copy of the Zacks research report on KemPharm (KMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply